On January 29, 2024, Executive Vice President Andrea Wainer executed a sale of 42,500 shares of Abbott Laboratories (NYSE:ABT), as reported in a recent SEC Filing.
Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the .
AbbottNew efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trialsAbbott's Diversity in Clinical Trials
Abbott (NYSE: ABT) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups .